The relationship between preliminary efficacy and prognosis after first-line EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment of advanced non-small cell lung cancer

BACKGROUND: Nowadays, patients with EGFR tyrosine kinase inhibitor (EGFR-TKI)-sensitive advanced non-small cell lung cancer (NSCLC) receive EGFR-TKIs as first-line treatment. We aimed to analyze the relationship between preliminary efficacy (tumor shrinkage within 1 month) and progression-free survi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Transl Med
Hlavní autoři: Chen, Dongfang, Chu, Tianqing, Chang, Qing, Zhang, Yanwei, Xiong, Liwen, Qiao, Rong, Teng, Jiajun, Han, Baohui, Zhong, Runbo
Médium: Artigo
Jazyk:Inglês
Vydáno: AME Publishing Company 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6545314/
https://ncbi.nlm.nih.gov/pubmed/31205913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.04.06
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky